Neurizon Therapeutics Limited (ASX:NUZ)

Neurizon Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	-	-	-	3.38	2.14
Other Revenue	1.54	0.84	0.87	1.13	1.52
Revenue	1.54	0.84	0.87	4.51	3.66
Revenue Growth (YoY)	82.70%	-3.66%	-80.63%	23.33%	-11.24%
Cost of Revenue	-	-	-	0.31	0.23
Gross Profit	1.54	0.84	0.87	4.2	3.43
Selling, General & Admin	6.28	2.44	1.5	4.74	3.85
Research & Development	11.68	3.85	1.03	0.76	0.55
Operating Expenses	18.48	6.66	2.52	5.82	4.7
Operating Income	-16.94	-5.82	-1.65	-1.62	-1.27
Interest Expense	-	-	-	-0.09	-0.08
Interest & Investment Income	0.34	0.02	0.08	0	0.01
EBT Excluding Unusual Items	-16.59	-5.79	-1.57	-1.71	-1.34
Asset Writedown	-	-3.11	-	-	-
Pretax Income	-16.59	-8.9	-1.57	-1.71	-1.34
Earnings From Continuing Operations	-16.59	-8.9	-1.57	-1.71	-1.34
Earnings From Discontinued Operations	-	1.23	-4.64	-	-
Net Income	-16.59	-7.67	-6.21	-1.71	-1.34
Net Income to Common	-16.59	-7.67	-6.21	-1.71	-1.34
Shares Outstanding (Basic)	487	371	321	317	316
Shares Outstanding (Diluted)	487	371	321	317	316
Shares Change (YoY)	31.44%	15.51%	1.30%	0.36%	6.66%
EPS (Basic)	-0.03	-0.02	-0.02	-0.01	-0.00
EPS (Diluted)	-0.03	-0.02	-0.02	-0.01	-0.00
Free Cash Flow	-14.29	-5.17	-1.6	-1.38	-1.04
Free Cash Flow Per Share	-0.03	-0.01	-0.01	-0.00	-0.00
Gross Margin	100.00%	100.00%	100.00%	93.03%	93.84%
Operating Margin	-1101.41%	-691.08%	-188.64%	-35.92%	-34.81%
Profit Margin	-1079.02%	-911.61%	-710.99%	-37.88%	-36.57%
Free Cash Flow Margin	-929.50%	-614.05%	-183.02%	-30.50%	-28.43%
EBITDA	-16.94	-5.82	-1.32	-1.45	-1.11
EBITDA Margin	-	-	-151.27%	-32.22%	-30.33%
D&A For EBITDA	0	0	0.33	0.17	0.16
EBIT	-16.94	-5.82	-1.65	-1.62	-1.27
EBIT Margin	-	-	-188.64%	-35.92%	-34.81%
Revenue as Reported	-	-	-	4.51	3.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.